

## ASX Announcement

### Spinal Cage FDA Submission Update

**SYDNEY 6 February 2024**—Further to the Spinal Cage FDA Submission Update, dated 5<sup>th</sup> December 2023, Allegra Medical Technologies (**Allegra**) (ASX: AMT) has taken the decision to not proceed with its formal submission to the Food & Drug Administration ('FDA') as previously planned. The Company has since received written confirmation of the withdrawal of the application from the FDA.

This decision was taken following recent communication with the FDA, resulting in Allegra recognising the need for additional supporting information to support its submission. Hence, Allegra has opted to voluntarily withdraw its submission to the FDA.

Given Allegra's limited working capital and the additional expense now required in obtaining supporting data for the Company's submission to the FDA, the Directors have now thoroughly explored all available options. After careful consideration, the preferred option is to go to the market to seek a buyer for all of the intellectual property relating to the Sr-HT-Gahnite and Sr-HT, including worldwide patents and all registered patents and application for patents in relation to the bio ceramic material, including the spinal fusion cage. The Company confirms that in undertaking taking this process any proposed sale will be subject to the required ASX and regulatory approvals.

Allegra will continue to update its shareholders on the progress of the above.

**This announcement has been authorised for release by the Chair of Allegra.**

Contact details:

**Robyn Slaughter**  
Company Secretary  
T: +61 2 8072 1435

#### **ABOUT ALLEGRA MEDICAL TECHNOLOGIES:**

Allegra Medical Technologies (AMT), a listed biotechnology company on the Australian Securities Exchange (ASX), is at the forefront of innovation in the medical device industry with its pioneering 3D-printed Sr-HT and Sr-HT-Gahnite orthopaedic devices. AMT holds exclusive ownership of this groundbreaking bio ceramic material, along with registered patents and patent applications from the University of Sydney. This versatile material has several applications, including its use as a cervical fusion cage in spinal surgeries, offering safe and effective treatment options for patients. The development of Sr-HT ceramic material began in 2010 at The University of Sydney, demonstrating the bioactivity required for bone regeneration. Subsequently, Sr-

#### **Allegra Medical Technologies Limited**

Level 8, 18 --- 20 Orion Rd, Lane Cove West NSW 2066 Australia; PO Box 72 St Leonards NSW 2065 Australia

**T** +612 9119 9200 **T** Toll Free 1800 644 370

**F** +612 9439 4441 **F** Toll Free 1800 624 223

**E** [sales@allegraorthopaedics.com](mailto:sales@allegraorthopaedics.com)

[www.allegraorthopaedics.com](http://www.allegraorthopaedics.com)



MEDICAL TECHNOLOGIES

HT-Gahnite was developed, featuring bioactivity, biocompatibility, and mechanical properties suitable for load-bearing orthopaedic implants. AMT boasts a dedicated, highly qualified engineering team with a clear mandate to explore, collaborate, and transform early-stage innovations into commercially viable products. Their primary focus currently centres on commercializing the Sr-HT Gahnite Bone substitute.

**Allegra Medical Technologies Limited**

Level 8, 18 --- 20 Orion Rd, Lane Cove West NSW 2066 Australia; PO Box 72 St Leonards NSW 2065 Australia

**T** +612 9119 9200 **T** Toll Free 1800 644 370

**F** +612 9439 4441 **F** Toll Free 1800 624 223

**E** [sales@allegraorthopaedics.com](mailto:sales@allegraorthopaedics.com)

[www.allegraorthopaedics.com](http://www.allegraorthopaedics.com)